Bringing Clinical Trials to Life

Dermatology

Together, Cu-Tech and Synteract create the leading dermatology CRO, with global capabilities and unparalleled access to sites and patients. Our focus on novel and required dermatology drugs provides dedicated research services unmatched in the market.
More...

Oncology

Like our clients, we are committed to the quest to cure cancer. But cancer is not just a single disease. It takes deep trial knowledge to know how to address its many forms. Learn how Synteract has stayed ahead of the trends leading towards new treatments…
More...

Neuro Degenerative

Neuro degenerative disorders are some of the most confounding and complex to affect people. Our specialized experience in these trials aids you in developing treatments that improve functioning and help the lives of both patients and caregivers…
More...

Rare & Orphan Diseases

Rare and orphan diseases have unique characteristics, not the least of which is finding the right population for your trials. We know the investigators and study sites that can help to address your recruitment goals, among other challenges…
More...

Pediatrics

Pediatric trials run the gamut of indications in drug development, but they all have primary things in common – working with children and their families requires specialized expertise and deep knowledge of regulatory requirements….
More...

9/23/2018 - 9/26/2018 : SCDM 2018 More...

8/1/2018: Respected team leader and motivator recognized for her passion and dedication in bringing clinical trials to life More ...

8/3/2018: Overcoming Challenges in Neuro Degenerative Clinical Trials - The number of neuro degenerative clinical trials is increasing with Parkinson’s, Alzheimer’s, Lou Gehrig’s, MS, and other neuro degenerative diseases growing in prevalence, especially as the population ages. Costs to society, caregivers, and patients are high.

Synteract Blog 

8/14/2018: "Ignoring pediatric considerations is no longer an option for development of new medicines, new indications, new dosing forms, new dosing regimens" said our VP of Pediatric Development, Dr. Martine Dehlinger-Kremer.  Learn more about pediatrics considerations in drug development in this Outsourcing-pharma article by Melissa Fassbender: https://lnkd.in/gx9A92x #clinicalresearch #clinicaldevelopment #pediatrics #pediatricresearch

Synteract on LinkedIn

8/14/2018: If you have #clinicalresearch, #biotech or #pharmaceutical experience and you’re looking for a company and career w… https://t.co/g5qSZRLshi

Synteract Twitter Feed
x

Contact Synteract

Tell us how to stay in touch with you:

*Required